Skip to content

Australian BioEnterics Intragastric Balloon (BIB) study in obese subjects with metabolic syndrome

A prospective, randomised, open-label, controlled study of safety and efficacy of the BioEnterics Intragastric Balloon (BIB) system in the treatment of obese participants with metabolic syndrome, with or without other obesity-related co-morbidities

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12608000224325
Enrollment
66
Registered
2008-04-30
Start date
2008-04-22
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Non-surgical intervention with intragastric balloon inserted into the stomach under endoscopic visualisation for a total of 6 months, as an adjunct to a 12 month behavioural management programme of supervised diet and exercise (A balanced diet high in whole grains, fruit and vegetables and with reduced fat intake. A moderate exercise regimen of at least 30 minutes/day will be instituted. This programme will be individualised and assessed each month by the study dietitian and the study exercise p

Non-surgical intervention with intragastric balloon inserted into the stomach under endoscopic visualisation for a total of 6 months, as an adjunct to a 12 month behavioural management programme of supervised diet and exercise (A balanced diet high in whole grains, fruit and vegetables and with reduced fat intake. A moderate exercise regimen of at least 30 minutes/day will be instituted. This programme will be individualised and assessed each month by the study dietitian and the study exercise physiologist and will be amended as required)

Sponsors

Allergan Australia
Lead SponsorCommercial sector/Industry

Study design

Allocation
Randomised controlled trial
Primary purpose
Treatment

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

(i) Body Mass Index (BMI) between 30 & 40 kg/m2 with metabolic syndrome (ii) Failed attempts to lose weight with supervised weight loss programmes

Exclusion criteria

Specific Gastrointenstinal [GI] diseases/conditions (e.g. inflammatory; bleeding; dysmotility) Prior gastric surgery; type 1 diabetes; untreated thyroid disease, hepatic or moderate to severe renal insufficiency; pregnancy; alcohol or drug dependence; psychiatric disorders; medication affecting weight or appetite

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026